Novo Nordisk Eyes Third Generic as 65% Price-Cut Trigger Looms

Novo Nordisk is bracing for a mandated 65% cut to its semaglutide list price in Canada once a third generic competitor reaches the market, according to comments made by the company's executive vice president of international operations on a recent earnings call [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html].

The third-generic threshold

Speaking on Novo Nordisk's earnings call, Emil Kongshøj Larsen said that once three generic competitors are on the Canadian market, policy mandates a 65% reduction to Novo's list price for Ozempic [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html]. Larsen said the company sees a "low single-digit" impact from generics and described its savings card as the "leading tactic" in Canada, with "very good uptake" reported for both Ozempic and Wegovy [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html].

Where the generic count stands

Health Canada authorized the first generic semaglutide injection from Dr. Reddy's Laboratories on April 28, 2026, making Canada the first G7 country to clear a generic version [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]. Three days later, on May 1, 2026, Health Canada authorized a second generic semaglutide injection, this one filed by Canadian-based Apotex [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html].

According to Health Canada's May 1 announcement, seven other generic semaglutide submissions from different companies remain under review, with regulatory decisions expected "in the coming weeks and months" [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html]. Any one of those seven, if cleared, would push the market past the third-generic threshold Larsen described.

Apotex launch timing

Apotex vice president of global communications Catherine Thomas told CBC News that the company's generic semaglutide should be available to Canadians within weeks, and that Apotex is working with health insurance companies on coverage [Source: cbc.ca/news/health/ozempic-semaglutide-generic-version-canada-9.7184915]. Thomas said: "For most private plans, the process to include generics happens shortly after launch" [Source: cbc.ca/news/health/ozempic-semaglutide-generic-version-canada-9.7184915].

Pan-Canadian Pharmaceutical Alliance tiers

CBC News reported that under the pricing structure of the pan-Canadian Pharmaceutical Alliance, the first generic medication can cost 75 to 85 per cent of the brand name [Source: cbc.ca/news/health/ozempic-semaglutide-generic-version-canada-9.7184915]. Once a second generic enters the market, the price for both drops to 50 per cent, and once three or more generic products are available the cost decreases to about 35 per cent of brand-name Ozempic's price [Source: cbc.ca/news/health/ozempic-semaglutide-generic-version-canada-9.7184915]. That 35% retail tier sits alongside the separate 65% list-price-cut trigger that Novo Nordisk referenced for its own brand pricing [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html].

What Novo says it will do

Larsen told analysts: "We know, sort of, the game there, and we are ready to play it, particularly with the savings card" [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html]. BMO Capital Markets analyst Evan Seigerman, cited in the same CNBC report, said the two Canadian generics likely mark the start of a decline in international revenue of semaglutide and that the firm will watch "how quickly pricing compression and revenue erosion impact Ozempic in the market as a proxy for other future generic entries" [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html].

Context for Canadian shoppers

Current pharmacy prices listed on GLP1Prices.ca range from $222 to $663 CAD for Ozempic, $270 to $490 for Wegovy, and $230 to $293.99 for Rybelsus. Tirzepatide products from Eli Lilly, including Mounjaro and Zepbound, are not affected by the semaglutide generic approvals. Readers tracking new entries can follow the generic semaglutide tracker, check the insurance coverage checker, or review the FAQ for further details.

This article is for informational purposes only and does not constitute medical advice.